Pacific Center for Emerging Infectious Diseases Research

University of Hawai'i Mānoa

COBRE/DEPT. OF TROPICAL MEDICINE SEMINAR

Antiviral Activity of Favipiravir Against Henipaviruses

Nipah virus (NiV) and Hendra virus are recently emerged bat-borne paramyxoviruses of the Henipavirus genus which cause severe acute respiratory and encephalitic diseases in humans. The case-fatality rate ranges from 40-90%, depending on the size of the outbreak. Currently, no vaccines or therapeutics are approved for use in humans. Favipiravir (T-705) is an RNA-dependent RNA polymerase inhibitor that has been approved for use against influenza virus in Japan and has displayed broad-spectrum efficacy against multiple RNA viruses (including filo-, arena- and bunyaviruses). Here, we demonstrate the in vitro activity of T-705 against henipaviruses and in vivo efficacy in a small animal model for NiV.

Alexander Freiberg, Ph.D.

Assistant Professor, Department of Pathology
Director, Robert E. Shope BSL-4 Laboratory
University of Texas Medical Branch
Galveston, Texas

Friday, May 20, 2016 at 12:00 noon
John A. Burns School of Medicine, Kaka'ako
Medical Education Building Auditorium (Room 315)
For further information, contact (808) 692-1654

The Center and its activities are supported by a grant (P30GM114737) from the National Institute of General Medical Sciences, National Institutes of Health.